Table 1 Baseline characteristics of persistent atrial fibrillation patients and their control
From: Amino acid profile alteration in age-related atrial fibrillation
|  | Control (n = 30) | Atrial fibrillation (n = 30) | P |
|---|---|---|---|
Age, y | 57.4 ± 9.9 | 58.3 ± 10.2 | 0.73 |
Male/Female | 14/16 | 15/15 | 1 |
Body mass index, kg/m2 | 24.09 ± 2.71 | 25.41 ± 3.52 | 0.174 |
Smoking, n (%) | 7 (23.3) | 5 (16.7) | 0.748 |
Alcohol intake, n (%) | 5 (16.7) | 5 (16.7) | 1 |
Systolic pressure, mmHg | 129.9 ± 16.6 | 124.7 ± 15.8 | 0.222 |
Diastolic pressure, mmHg | 82.7 ± 11.8 | 81.3 ± 14.1 | 0.675 |
Hypertension, n (%) | 13 (43.3) | 17 (56.7) | 0.439 |
Diabetes, n (%) | 3 (10.0) | 6 (20.0) | 0.472 |
Coronary heart disease, n (%) | 7 (23.3) | 9 (30) | 0.771 |
Triglyceride (mmol/L) | 1.22 (0.95, 2.49) | 1.34 (0.96,1.67) | 0.229 |
Total cholesterol (mmol/L) | 4.58 ± 0.98 | 3.97 ± 0.73 | 0.008 |
High-density lipoprotein cholesterol (mmol/L) | 1.11 ± 0.25 | 1.15 ± 0.20 | 0.575 |
Low-density lipoprotein cholesterol (mmol/L) | 2.94 ± 0.82 | 2.38 ± 0.70 | 0.006 |
Free triiodothyronine (pmol/L) | 3.25 ± 0.91 | 3.41 ± 1.62 | 0.668 |
Free thyroxine (pmol/L) | 4.48 ± 6.01 | 4.84 ± 6.89 | 0.839 |
Thyroid-stimulating hormone (mIU/L) | 4.38 ± 8.87 | 2.54 ± 2.12 | 0.284 |
Creatine kinase (U/L) | 83.61 ± 36.82 | 100.99 ± 64.34 | 0.224 |
Creatine kinase isoenzyme (CK-MB) (U/L) | 17.53 ± 16.81 | 16.65 ± 5.12 | 0.798 |
Alanine aminotransferase (U/L) | 19.74 ± 9.57 | 23.97 ± 14.95 | 0.204 |
Aspartate aminotransferase (U/L) | 19.80 ± 4.78 | 22.69 ± 7.01 | 0.07 |
Creatinine | 84.64 ± 85.31 | 77.26 ± 17.38 | 0.644 |
C-reactive protein | 2.07 ± 3.44 | 1.36 ± 2.35 | 0.417 |
Left atrial diameter (mm) | 33.07 ± 3.47 | 43.45 ± 5.08 |  < 0.001 |
Right atrial diameter (mm) | 31.52 ± 3.21 | 38.24 ± 5.03 |  < 0.001 |
Left ventricular ejection fraction (%) | 62.15 ± 3.90 | 55.86 ± 7.20 |  < 0.001 |